Although market SP is manipulated, IER will weigh in Sleepcheck FDA, Cough sound patent, and the data confirmation result. I will be surprised if the valuations are same as it was. However nobody, including Pfizer, want to waste a few more weeks to amend the already ASIC submitted scheme (Manipulation has a cost, and quarterly figure is coming). The exception is they have to based on IER revised value.
Ann: ResApp receives FDA 510(k) clearance for SleepCheckRx, page-42
Currently unlisted. Proposed listing date: 4 SEPTEMBER 2024 #
